Text Size
4123 studies found for:    lymphoma

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
Conditions: Burkitt Lymphoma;   Diffuse Large B-cell Lymphoma, c-MYC Positive
Interventions: Drug: rituximab;   Drug: etoposide;   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: vincristine;   Drug: prednisone;   Drug: filgrastim
2 Active, not recruiting Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
Conditions: Follicular Lymphoma;   Marginal Zone Lymphoma
Interventions: Drug: azacitidine;   Drug: lenalidomide
3 Recruiting Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Conditions: Lymphoma;   Nonneoplastic Condition
Interventions: Genetic: polymerase chain reaction;   Other: laboratory biomarker analysis
4 Recruiting Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Drug: Rituximab;   Drug: Lenalidomide;   Drug: Rituximab-CHOP;   Drug: Rituximab-CVP;   Drug: Rituximab-Bendamustine
5 Completed Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma
Conditions: Non-Hodgkin's Lymphoma;   Mantle Cell Lymphoma
Intervention: Drug: bendamustine hydrochloride
6 Withdrawn Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma
Conditions: Mantle Cell Lymphoma;   Lymphoma
Intervention: Procedure: PET/CT Scanning
7 Active, not recruiting Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Drug: Rituximab;   Drug: Etoposide
8 Recruiting Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: bortezomib;   Drug: carboplatin;   Drug: dexamethasone;   Drug: etoposide;   Drug: ifosfamide;   Genetic: polymerase chain reaction;   Genetic: western blotting
9 Recruiting Bortezomib and Romidepsin in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Indolent B-cell Lymphoma, Peripheral T-cell Lymphoma or Cutaneous T-Cell Lymphoma
Conditions: Leukemia;   Lymphoma
Interventions: Drug: Bortezomib;   Drug: Romidepsin
10 Completed Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma
Conditions: Mantle Cell Lymphoma;   B Cell Lymphoma;   Multiple Myeloma
Intervention: Drug: Canfosfamide HCl for injection
11 Active, not recruiting Imexon for Relapsed Follicular and Aggressive Lymphomas
Conditions: Follicular Lymphoma;   Small Lymphocytic Lymphoma;   Marginal Zone Lymphoma;   Lymphoplasmacytic Lymphoma;   Diffuse Large B Cell Lymphoma;   Mantle Cell Lymphoma;   Burkitt's Lymphoma
Intervention: Drug: Imexon
12 Unknown † Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Non-Hodgkin's Lymphoma (Follicular, Diffuse Large Cell, Mantle Cell, and Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia
Conditions: Non-Hodgkin's Lymphoma;   Follicular Lymphoma;   Diffuse Large Cell Lymphoma;   Mantle Cell Lymphoma;   Small Lymphocytic Lymphoma;   Chronic Lymphocytic Leukemia
Intervention: Biological: ISF35
13 Active, not recruiting Biaxin Based Antibiotic Therapy in Previously Untreated, Advanced Stage Indolent Lymphoma
Condition: Lymphoma
Interventions: Drug: BIAXIN (CLARITHROMYCIN);   Drug: Biaxin (clarithromycin)
14 Completed
Has Results 		17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma
Condition: Lymphoma
Intervention: Drug: 17-AAG (Tanespimycin)
15 Unknown † Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma
Conditions: Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine;   Biological: autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine;   Biological: autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine
16 Recruiting Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
Conditions: Hodgkin Lymphoma;   Anaplastic Large-cell Lymphoma
Intervention: Drug: brentuximab vedotin
17 Completed
Has Results 		Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma
Condition: Lymphoma
Intervention: Drug: Flavopiridol
18 Unknown † Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma
Conditions: Peripheral T-cell Lymphoma (Not Otherwise Specified);   Angioimmunoblastic T-cell Lymphoma;   Extranodal NK/T-cell Lymphoma Nasal Type;   Enteropathy- Type T-cell Lymphoma;   Hepatosplenic T-cell Lymphoma;   Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative);   Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant
Intervention: Drug: panobinostat and bortezomib
19 Recruiting Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma
Conditions: Follicular Lymphoma;   Mantle Cell Lymphoma
Intervention: Drug: Temsirolimus, Rituximab, Bendamustin
20 Suspended Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat
Conditions: Hodgkin's Lymphoma;   Low Grade Lymphoma;   Lymphoma;   Mantle Cell Lymphoma;   Non-Hodgkin's Lymphoma;   Diffuse Large Cell Lymphoma
Interventions: Drug: AMG 655;   Other: Vorinostat;   Other: Bortezomib
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years